BioSpace News Archive

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks: 2021 Oncology Day on Thursday, February 11 at 4:30 p.m. ET.

Certara, the global leader in biosimulation, today announced that it has published a white paper on how biosimulation can be used to optimize the world’s limited supply of COVID-19 vaccines.

Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 CheckMate -274 trial, which showed that Opdivo (nivolumab) significantly improved disease-free survival (DFS) as an adjuvant treatment across all randomized patients with surgically resected,

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the appointment of Susan Moriconi as VP of People and Chief Human Resources Officer.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), announces that it has filed a Form 51-102F4 Business Acquisition Report (BAR) pursuant to National Instrument 51-102 Continuous Disclosure Obligations in connection with its acquisition of Psilocin Pharma Corp. on March 5, 2020.‎

RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF) (“Relief” or the “Company”) affirms that its collaboration partner NeuroRx, Inc. has initiated a phase 2/3 clinical trial investigating the role of inhaled RLF-100TM (aviptadil; ZYESAMI(TM)) for the treatment of patients with severe COVID-19 in partnership with UCI Health of the University of California, Irvine.

Scopus BioPharma Inc. announced that the underwriters of the company’s follow-on public offering exercised their over-allotment option in full, bringing total proceeds to $10.35 million.

ShiraTronics, Inc. a privately held medical device company, announced today that it has been granted a Breakthrough Device designation by the Center of Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for its innovative neurostimulation therapy targeting the millions of chronic migraine sufferers.

Yingli Pharma announced today that it reached strategic collaboration with Hengrui Medicine (600276.SH), a partnership which will significantly accelerate the expansion of Yingli Pharma’s oncology business in China, the second largest pharmaceutical market in the world.

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited fourth quarter and full year 2020 financial results before the U.S. market opens on March 11, 2021.